• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Pfizer, BioNTech seek EUA for booster against COVID-19 Omicron variant


Novavax vaccine recommended for youths; FDA updates fact sheets on Paxlovid.

Pfizer, BioNTech seek EUA for booster against COVID-19 Omicron variant

As autumn approaches with possibilities of COVID-19 surges, Pfizer and BioNTech are seeking federal emergency use authorization (EUA) for a booster vaccine against the Omicron BA.4/BA.5 variant.

The U.S. Food and Drug Administration will consider EUA for a booster dose for people aged 12 years and older and if approved, the vaccine will be available to ship immediately, according to the announcement from the companies.

“The agility of the mRNA platform, together with extensive clinical experience with the Pfizer-BioNTech COVID-19 Vaccine, has allowed us to develop, test and manufacture updated, high-quality vaccines that align to circulating strains with unprecedented speed,” Pfizer Chairman and CEO Albert Bourla said in a news release. “Having rapidly scaled up production, we are positioned to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters, if authorized, to help protect individuals and families as we prepare for potential fall and winter surges."

A conditional marketing authorization application has also been initiated with the European Medicines Agency (EMA) for the Omicron BA.4/BA.5-adapted bivalent vaccine and is expected to be completed in the coming days.

“Given the ongoing evolution of SARS-CoV-2 and its variants, it's of great importance that vaccines can be rapidly adapted to the major circulating Omicron lineages,” BioNTech CEO and cofounder Prof. Ugur Sahin, MD, said in the news release. “In less than three months after the FDA provided its guidance for adapted vaccines in the U.S., we are ready to ship the first doses of our Omicron BA.4/BA.5-adapted bivalent vaccine, pending regulatory authorization, to provide people in the U.S. with the possibility to get a booster adapted to the currently most dominant strain of the virus.”

The Pfizer and BioNTech announcement said the bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. “Preclinical data showed a booster dose of the Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response” against the Omicron variants and the original strain.


On Aug. 19, FDA authorized the emergency use of the Novavax COVID-19 vaccine, adjuvanted, for youths aged 12 to 17 years. The EUA follows emergency authorization in July for the Novavax vaccine for people aged 18 years and older.

The U.S. Centers for Disease Control and Prevention (CDC) announced Director Rochelle P. Walensky, MD, MPH, on Aug. 22 signed a memo for the Novavax vaccine, also known as NVX-CoV2373, to be an option for adolescents.

CDD noted the Novavax shot uses proteins of the COVID-19 virus with an adjuvant to activate the human immune system. It is different from the Pfizer-BioNTech mRNA vaccines and the protein technology has been used more than 30 years in the United States in vaccines for diseases such as hepatitis B, inflenza and whooping cough.

“Novavax’s COVID-19 vaccine, which is available now, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents,” the CDC statement said. “Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.”


This month, FDA reissued its letter of EUA for Pfizer’s Paxlovid for the treatment of mild to moderate COVID-19 in adults and youths aged 12 years and older, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The pharmaceutical maker must conduct a clinical trial for patients with “COVID-19 rebound” and a clinical trial to evaluate treatment durations for immunocompromised patients with mild to moderate COVID-19, according to FDA.

The federal agency this month published Pfizer’s updated prescribing and dispensing information for Paxlovid for oral use. It is made up of the tablets nirmatrelvir and ritonavir and Pfizer “has become aware of reports of wrong-dose medication errors,” largely due to patients taking the wrong combination of tablets that are copackaged in blister cards.

The updated fact sheet explains how physicians and prescribing clinicians should inform patients on how to correctly take the doses.

Related Videos